CollPlant Biotechnologies (CLGN) Exchange Rate Effect (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Exchange Rate Effect came in at -$6000.0 in Q4 2025, down 110.0% YoY from $60000.0 in Q4 2024, and up 33.33% on a QoQ basis from -$9000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Exchange Rate Effect (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Exchange Rate Effect data on file, last reported at -$6000.0 in Q4 2025.
- Quarterly Exchange Rate Effect fell 110.0% year-over-year to -$6000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $85000.0 (up 159.86% YoY) and the FY2025 annual result came in at $26000.0, up 118.31% from the prior year.
- Exchange Rate Effect improved to -$6000.0 in Q4 2025, from -$9000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $955000.0 in Q2 2022 to a low of -$1.4 million in Q3 2022.
- A 5-year average of -$87368.4 and a median of -$9000.0 in 2025 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 1636.36% in 2022, down 47633.33% in 2022.
- Tracing CLGN's Exchange Rate Effect over 5 years: stood at $153000.0 in 2021, then slumped by 497.39% to -$608000.0 in 2022, then soared by 132.73% to $199000.0 in 2023, then sank by 69.85% to $60000.0 in 2024, then tumbled by 110.0% to -$6000.0 in 2025.
- The last three Exchange Rate Effect figures came in at -$6000.0 (Q4 2025), -$9000.0 (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Dec 31, 2023 | 199,000.00 |
| Dec 31, 2023 | 199,000.00 |
| Sep 30, 2023 | -134,000.00 |
| Sep 30, 2023 | -134,000.00 |
| Jun 30, 2023 | -162,000.00 |
| Jun 30, 2023 | -162,000.00 |